secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001645113-23-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Q1 2023: Revenue down 11% to $122M, net loss $53.1M, prescriptions up 8%
--------------------------------------------------------------------------------

- Total net revenues $122.2M (-11% YoY); US $85.2M, Germany $15.1M, Japan $8.7M.
- Net loss $53.1M ($0.50 loss per share); adjusted EBITDA -$18.4M.
- Prescriptions received 1,496 (+8% YoY); active patients 3,467 as of March 31.
- R&D expenses +41% to $59.7M on clinical trial activity; sales & marketing +35%.
- Phase 3 LUNAR NSCLC data to be presented at ASCO June 6; METIS enrollment completed, data Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/0001645113-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/nvcr-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer